Fig. 4: Kaplan Meier plot of progression free survival and overall survival in the patients with TNBC. | Nature Communications

Fig. 4: Kaplan Meier plot of progression free survival and overall survival in the patients with TNBC.

From: Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study

Fig. 4

Kaplan–Meier progression-free survival (a) and overall survival (b) curves in the patients with TNBC. a The median PFS was 4.8 months (95% CI 3.2–5.8). b The median OS was 14.1 months (95% CI 11.2-not reached), the OS rate was 59.3% (95% CI 47.7–69.1) at 12 months and 47.3% (95% CI 34.8–58.9) at 18 months. TNBC triple negative breast cancer. Source data are provided as a Source Data file.

Back to article page